← back to database
We focus on high-growth, disruptive businesses with innovative products and services that have a proven business model in sectors where we believe the upside is enormous.
Primary stage
Lead / follow
Initial check size
Ownership target
Generalist / Specialist
Generalist
Does not invest in
Biotech, pharma
Investing team
- Andy AppelbaumManaging Partner
- Danny CohenPrincipal
- Spencer KrugPartner